MedTrace Logo

Quetiapine for Cocaine Use and Cravings

NCT00232336 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2024-04-19

No results posted yet for this study

Summary

The purpose of this study was to collect pilot data on whether quetiapine may be effective in the reduction of cocaine use and cravings in cocaine dependent individuals.

Conditions

  • Cocaine-Related Disorders
  • Substance-Related Disorders

Interventions

DRUG

quetiapine

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Seattle Institute for Biomedical and Clinical Research

    lead OTHER

Principal Investigators

  • Andre Tapp, M.D. · VA Puget Sound Health Care System, Tacoma and Seattle, WA and University of Washington, Department of Psychiatry and Behavioral Sciences, Seattle, WA

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-10-31
Primary Completion
2006-01-31
Completion
2006-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00232336 on ClinicalTrials.gov